B+
Bull case
25%
Probability
Target price
$45.00
Analysis reference price unavailable
Analysis 2026-08-24 · RankAlpha Sentiment Codex
IMNM
ImmunomeANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
RINGSIDE produced statistically significant primary and key secondary endpoint results, varegacestat has entered FDA review with a defined PDUFA date, and $520.0 million of cash, cash equivalents, and marketable securities is expected to fund operations into 2028. Multiple additional oncology programs provide further milestone optionality.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +8.6.
What can break
IM-1021, IM-1617, IM-3050, and preclinical ADC programs remain dependent on early clinical execution, enrollment, safety, and data quality.
Momentum
78
Value
41
Sentiment
88
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $31.00 · Bull $45.00 · Bear $20.00Analysis 2026-08-24; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-24 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $36.31
Why
Momentum78 · Δ7d -3.7
Value41 · Δ7d 0.0
Sentiment88 · Δ7d +8.6
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +8.6.
Contradictions & invalidation
- • IM-1021, IM-1617, IM-3050, and preclinical ADC programs remain dependent on early clinical execution, enrollment, safety, and data quality.
- • No reliable company-provided consensus comparison or complete post-print estimate-revision series is available; the positive analyst target changes are limited and secondary-source based.
- • The company remains loss-making and pre-commercial, with a $73.1 million quarterly net loss and $59.9 million of quarterly R&D expense.
Catalyst clock
2026-08-24
Post-earnings pipeline execution remains the near-term read-through
Lead driver: Sentiment · See AI snapshot
Momentum
78
9% active weight
Current posture
7d trendFlat
Δ7d
-3.7
Δ21d
-10.6
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
88
62% active weight
Current posture
7d trendImproving
Δ7d
+8.6
Δ21d
+1.1
Why this grade
Composite grade A. Momentum 78.4 / Value 41.2 / Sentiment 87.6
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-24. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$31.00
Analysis reference price unavailable
Analysis 2026-08-24 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$20.00
Analysis reference price unavailable
Analysis 2026-08-24 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$3.11B
Beta
2.33
Shares Out
113.58M
P/E (TTM) · Derived
-11.3
P/S (TTM)
224.68
P/FCF (TTM) · Derived
-12.80
Rev YoY
-100.0%
EPS YoY
+29.4%
Gross Margin
+25.7%
Op Margin
-2419.9%
Net Debt
-$649.63M
Current Ratio
15.08
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data